CLINICAL ACTIVITY OF ICT01, AN ANTI-BTN3A-2021; J Immunother Cancer Dresden, Germany, Dresden, Germany

rapidly activate with solid tumors that showed microgram doses of ICT01

Background We presented EVICTION Trial data from patients

3Institut Jules Bordet, Brussels, Belgium

1Leo Rhunke, 9Aude de Gassart, 9Patrick Brune, 9Emmanuel Valentin, 10Marina Iche, 2Stephane Champiat, 1Catrin List, 6Vladimir Galvaö de Aguiar, 1Katrin Wetzko, 5Norbert Vey, 5Cécile Vicier, 6Elena Garralda, 7Steven Le Gouill, 8Patricia LoRusso, 1Martin Wermke*, 2Aurelien Marabelle, 3Christiane Jungels, 4Johann De Bono, 9Daniel Olive, 11, 9Paul Frohna.

consulting, Argenteuil, France

Marsden, London, UK, London, UK

#316, SITC 2020). Confirming tumor infiltration of activated γ982 T cells and the subsequent clinical benefit are the next steps in characterizing the therapeutic potential of ICT01.

Methods EVICTION is an ongoing Phase 1/2a, EU and US trial assessing ICT01 monotherapy (IV Q3W) in advanced/refractory solid and hematologic cancers, and ICT01 in combination with pembrolizumab (200mg IV Q3W) in solid tumor patients who failed ≥1 CPI. Pharmacodynamic activity was monitored by immunophenotyping and cytokine level analysis. Tumor biopsies (baseline, Day 28) were used for immunohistochemistry of BTN3A and tumor-infiltrating lymphocytes, and gene expression profiling. Efficacy evaluations were conducted every 8 weeks.

Results ICT01 monotherapy dose escalation (20μg to 200mg IV ICT01 Q3W) in solid tumor patients (Group A, n=32) has been completed, and 3 dose cohorts of ICT01 (700μg, 2 and 7 mg) plus Pembrol (Group C, n=12) were completed; both without any DLTs. First-dose fever and chills (Grade 1/2) were the most common AEs that increased in frequency but were both without any DLTs. First-dose fever and chills (Grade 1/2) post ICT01 induced trafficking of >95% of circulating γ982 T cells within 30 min post ICT01 (>2mg), which was sustained for 21 days at doses ≥75mg. Transient, dose-dependent increases in serum cytokines at 30 min (TNFα) or 4h (IFNγ) post-dose were correlated with baseline γ982 T cell counts and with activation and migration of NK and CD8 T cells out of the blood at doses ≥7mg. Higher baseline circulating γ982 T cells and lower TILs were associated with more robust intra-tumoral increases in total γδ(3–34x increase), CD3 (3–55x increase) and CD8 T cells (1.3–66x increase), which demonstrated the potential to transform an immune desert tumor phenotype. Disease control by ITT analysis of RECIST1.1 data was observed in 6/32 (SD) and 4/7 patients (3 SD (bladder, melanoma, NSCLC), 1 PR (bladder)) in Groups A and C, respectively, with 5/6 patients at 7mg in Group C not yet evaluable.

Conclusions These results show a broad antitumor immune response in the blood and tumors comprising γ982, CD8 T cell, and NK cell activation and tumor-infiltration following ICT01 alone and in combination with pembrolizumab. Preliminary efficacy data suggest low-dose ICT01 plus pembrolizumab may be more effective than ICT01 monotherapy for advanced/refractory solid tumors, which requires confirmation.

Acknowledgements Lena Daher for her medical/scientific writing support.

Trial Registration www.clinicaltrials.gov NCT04243499; EudraCT Number: 2019-003847-31

Ethics Approval This study was approved by the following Ethics Committees: COMITE DE PROTECTION DES PERSONNES, Sud-Méditerranéen V (Gustave Roussy, IPC, Nantes), Comité d'Éthique Institut Jules Bordet, COMITÉ DE ÉTICA DE INVESTIGACIÓN CLÍNICA CON MEDICAMENTOS del Hospital Universitari Vall d’Hebron, Ethikkommission an der TU Dresden, HRA London-Surrey Borders Research Ethics Committee.

Consent Written informed consent was obtained from the patient for publication of this abstract and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.

http://dx.doi.org/10.1136/jitc-2021-SITC2021.503